New MGD treatment holds promise

A novel therapy for meibomian gland dysfunction (MGD), developed from treatment for a chronic form of dermatitis and dandruff, holds promise for a better solution option for dry eye disease (DED). AZR-MD-001 is the first ophthalmic keratolytic for the treatment of lid margin diseases such as MGD, blepharitis and contact lens discomfort...

 

Māori and Pasifika, and ophthalmology

The Royal Australian and New Zealand College of Ophthalmologists (RANZCO) has identified indigenous workforce development as a priority. Tackling this...

Wait… you want what?!

Fierce rivalry and battles of wit, experience and education have been raging for more than a century. Often characterised by the odd bruised eye, bruised...

Dry eye technology: improving outcomes

My practice focuses on specialty eye care and, much to my surprise, dry eye continues to be one of our main drawcards and is continuing to grow. A lot...

DED and immune-mediated diseases

The most severe forms of chronic dry eye disease (DED) are often caused by underlying immune-mediated diseases. These can be visually debilitating in some...

Battling OSD despite the pandemic

No one could have imagined what 2020 would bring, least of all those in the eye professions for whom ‘2020’, by all rights, was supposed to be our ‘perfect’...

Bottom Banner Advert